Current biology of VEGF-B and VEGF-C

Current Opinion in Biotechnology

Volumn 10, Issue 6, 1999, Pages 528-538

  Olofsson, Birgitta ^a   Jeltsch, Michael ^b   Eriksson, Ulf ^a   Alitalo, Kari ^b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPILIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; GENE EXPRESSION REGULATION; GENE STRUCTURE; LYMPH VESSEL ENDOTHELIUM; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 0032735698     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(99)00024-5     Document Type: Review

References (86)

1. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
2. Wang H.U., Chen Z.F., Anderson D.J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4 [see comments]. Cell. 93:1998;741-753. A genetic distinction between small arteries and veins.
3. Adams R.H., Wilkinson G.A., Weiss C., Diella F., Gale N.W., Deutsch U., Risau W., Klein R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 13:1999;295-306.
4. Fong G.H., Rossant J., Gertsenstein M., Breitman M. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of the vascular endothelium. Nature. 376:1995;66-70.
5. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., Schuh A.C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:1995;62-66.
6. Sato T.N., Tozawa Y., Deutsch U., Wolburg-Buchholz K., Fujiwara Y., Gendron-Maguire M., Gridley T., Wolburg H., Risau W., Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 376:1995;70-74.
7. Puri M.C., Rossant J., Alitalo K., Bernstein A., Partanen J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 14:1995;5884-5891.
8. Dumont D.J., Gradwohl G., Fong G.H., Puri M.C., Gertsenstein M., Auerbach A., Breitman M.L. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 8:1994;1897-1909.
9. Dumont D.J., Jussila L., Taipale J., Lymboussaki A., Mustonen T., Pajusola K., Breitman M., Alitalo K. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science. 282:1998;946-949. This early lethal phenotype of mice deficient in VEGFR-3 clearly illustrates that VEGFR-3 is essential for normal vascular remodelling and maturation.
10. Korpelainen E.I., Alitalo K. Signaling angiogenesis lymphangiogenesis. Curr Opin Cell Biol. 10:1998;159-164.
11. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
12. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 143:1993;401-409.
13. Kerbel R.S. A cancer therapy resistant to resistance [see comments]. Nature. 390:1997;335-336.
14. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:1995;27-31.
15. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 146:1995;1029-1039.
16. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Rev. 18:1997;4-25.
17. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C.et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:1996;435-439.
18. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'.Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:1996;439-442.
19. Gerber H.P., Hillan K.J., Ryan A.M., Kowalski J., Keller G.A., Rangell L., Wright B.D., Radtke F., Aguet M., Ferrara N. VEGF is required for growth and survival in neonatal mice. Development. 126:1999;1149-1159. Inactivation of VEGF in newborn mice indicates that VEGF is essential during early postnatal life but this VEGF dependence is lost upon maturation.
20. Clauss M., Gerlach M., Gerlach H., Brett J., Wang F., Familletti P.C., Pan Y.C., Olander J.V., Connolly D.T., Stern D. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 172:1990;1535-1545.
21. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 87:1996;3336-3343.
22. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1996;1096-1103.
23. Korpelainen E.I., Karkkainen M.J., Tenhunen A., Lakso M., Rauvala H., Vierula M., Parvinen M., Alitalo K. Overexpression of VEGF in testis and epididymis causes infertility in transgenic mice: evidence for nonendothelial targets for VEGF. J Cell Biol. 143:1998;1705-1712. This is a demonstration of non-endothelial target cells in testis and the involvement of VEGF in male fertility.
24. Midy V., Plouet J. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem Biophys Res Commun. 199:1994;380-386.
25. Gerber H.P., Vu T.H., Ryan A.M., Kowalski J., Werb Z., Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med. 5:1999;623-628.
26. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 92:1998;735-745.
27. Carmeliet P., Ng Y.S., Nuyens D., Theilmeier G., Brusselmans K., Cornelissen I., Ehler E., Kakkar V.V., Stalmans I., Mattot V.et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med. 5:1999;495-502. Mice exclusively expressing the VEGF120 isoform show severe phenotype in the heart leading to fatal ischemic cardiomyopathy. In wild-type embryos, the expression of the longer isoforms of VEGF, VEGF164 and VEGF188, dominate in the heart. Thus, this data demonstrates the different functional roles of the VEGF isoforms.
28. Veikkola T., Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol. 9:1999;211-220.
29. Paavonen K., Horelli-Kuitunen N., Chilov D., Kukk E., Pennanen S., Kallioniemi O.P., Pajusola K., Olofsson B., Eriksson U., Joukov V.et al. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. Circulation. 93:1996;1079-1082.
30. Grimmond S., Lagercrantz J., Drinkwater C., Silins G., Townson S., Pollock P., Gotley D., Carson E., Rakar S., Nordenskjold M., Alitalo K.et al. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res. 6:1996;124-131.
31. Olofsson B., Pajusola K., von Euler G., Chilov D., Alitalo K., Eriksson U. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem. 271:1996;19310-19317.
32. Townson S., Lagercrantz J., Grimmond S., Silins G., Nordenskjold M., Weber G., Hayward N. Characterization of the murine VEGF-related factor gene. Biochem Biophys Res Commun. 220:1996;922-928.
33. Olofsson B., Korpelainen E., Pepper M.S., Mandriota S.J., Aase K., Kumar V., Gunji Y., Jeltsch M.M., Shibuya M., Alitalo K. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA. 95:1998;11709-11714. The first demonstration that VEGF-B selectively interacts with VEGFR-1.
34. Mäkinen T., Olofsson B., Karpanen T., Hellman U., Soker S., Klagsbrun M., Eriksson U. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem. 274:1999;21217-21222. An example of how proteolytic processing can regulate receptor specificity. See also [43], which demonstrated the functional consequence of proteolytic processing of VEGF-C, that is, the activation of VEGFR-2 by the processed form of VEGF-C only.
35. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15:1996;290-298.
36. Lee J., Gray A., Yuan J., Luoh S.M., Avraham H., Wood W.I. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA. 93:1996;1988-1992.
37. Orlandini M., Marconcini L., Ferruzzi R., Oliviero S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci USA. 93:1996;11675-11680. [Published erratum appears in Proc Natl Acad Sci USA 1997, 94:1603.].
38. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F., Alitalo K., Stacker S.A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA. 95:1998;548-553. A novel member of the VEGF family.
39. Yamada Y., Nezu J., Shimane M., Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics. 42:1997;483-488.
40. Chilov D., Kukk E., Taira S., Jeltsch M., Kaukonen J., Palotie A., Joukov V., Alitalo K. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem. 272:1997;25176-25183.
41. Maglione D., Guerriero V., Viglietto G., Delli-Bovi P., Persico M.G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA. 88:1991;9267-9271.
42. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., Abraham J.A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 266:1991;11947-11954.
43. Joukov V., Sorsa T., Kumar V., Jeltsch M., Claesson-Welsh L., Cao Y.H., Saksela O., Kalkkinen N., Alitalo K. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16:1997;3898-3911.
44. Heldin C.H., Östman A., Westermark B. Structure of platelet-derived growth factor: implications for functional properties. Growth Factors. 8:1993;245-252.
45. Silins G., Grimmond S., Egerton M., Hayward N. Analysis of the promoter region of the human VEGF-related factor gene. Biochem Biophys Res Commun. 230:1997;413-418.
46. Rocchigiani M., Lestingi M., Luddi A., Orlandini M., Franco B., Rossi E., Ballabio A., Zuffardi O., Oliviero S. Human FIGF: cloning, gene structure, and mapping to chromosome Xp22.1 between the PIGA and the GRPR genes. Genomics. 47:1998;207-216.
47. Enholm B., Paavonen K., Ristimaki A., Kumar V., Gunji Y., Klefstrom J., Kivinen L., Laiho M., Olofsson B., Joukov V.et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene. 14:1997;2475-2483.
48. Ristimäki A., Narko K., Enholm B., Joukov V., Alitalo K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem. 273:1998;8413-8418.
49. Laitinen M., Ristimaki A., Honkasalo M., Narko K., Paavonen K., Ritvos O. Differential hormonal regulation of vascular endothelial growth factors VEGF, VEGF-B, and VEGF-C messenger ribonucleic acid levels in cultured human granulosa-luteal cells. Endocrinology. 138:1997;4748-4756.
50. Ruohola J.K., Valve E.M., Karkkainen M.J., Joukov V., Alitalo K., Harkonen P.L. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol. 149:1999;29-40.
51. Olofsson B., Pajusola K., Kaipainen A., von Euler G., Joukov V., Saksela O., Orpana A., Pettersson R.F., Alitalo K., Eriksson U. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA. 93:1996;2576-2581.
52. Aase K., Lymboussaki A., Kaipainen A., Olofsson B., Alitalo K., Eriksson U. Localization of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature. Dev Dyn. 215:1999;12-25.
53. Lagercrantz J., Larsson C., Grimmond S., Fredriksson M., Weber G., Piehl F. Expression of the VEGF-related factor gene in pre- and postnatal mouse. Biochem Biophys Res Commun. 220:1996;147-152.
54. Lagercrantz J., Farnebo F., Larsson C., Tvrdik T., Weber G., Piehl F. A comparative study of the expression patterns for vegf, vegf-b/vrf and vegf-c in the developing and adult mouse. Biochim Biophys Acta. 1398:1998;157-163.
55. Kukk E., Lymboussaki A., Taira S., Kaipainen A., Jeltsch M., Joukov V., Alitalo K. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development. 122:1996;3829-3837.
56. Eichmann A., Corbel C., Jaffredo T., Breant C., Joukov V., Kumar V., Alitalo K., le Douarin N.M. Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors. Development. 125:1998;743-752. This work demonstrates that VEGF and VEGF-C can act in a redundant fashion via VEGFR-2.
57. Fitz L.J., Morris J.C., Towler P., Long A., Burgess P., Greco R., Wang J., Gassaway R., Nickbarg E., Kovacic S.et al. Characterization of murine Flt4 ligand/VEGF-C. Oncogene. 15:1997;613-618.
58. Keyt B.A., Nguyen H.V., Berleau L.T., Duarte C.M., Park J., Chen H., Ferrara N. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem. 271:1996;5638-5646.
59. Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A., de Vos A.M. Crystal structure at 1.7 Angstrom resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell. 91:1997;695-704.
60. Migdal M., Huppertz B., Tessler S., Comforti A., Shibuya M., Reich R., Baumann H., Neufeld G. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem. 273:1998;22272-22278.
61. Kitsukawa T., Shimono A., Kawakami A., Kondoh H., Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development. 121:1995;4309-4318.
62. Kitsukawa T., Shimizu M., Sanbo M., Hirata T., Taniguchi M., Bekku Y., Yagi T., Fujisawa H. Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron. 19:1997;995-1005.
63. Fairbrother W.J., Champe M.A., Christinger H.W., Keyt B.A., Starovasnik M.A. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure. 6:1998;637-648.
64. Taipale J., Makinen T., Arighi E., Kukk E., Karkkainen M., Alitalo K. Vascular endothelial growth factor receptor-3. Curr Topics Microbiol Immunol. 237:1999;85-96.
65. Joukov V., Kumar V., Sorsa T., Arighi E., Weich H., Saksela O., Alitalo K. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem. 273:1998;6599-6602. A mutant of VEGF-C is described that interestingly has lost both the ability to activate VEGFR-2 and to induce vascular permeability.
66. Fong G.H., Zhang L., Bryce D.M., Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development. 126:1999;3015-3025.
67. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA. 95:1998;9349-9354.
68. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 367:1994;576-579.
69. Goldman C.K., Kendall R.L., Cabrera G., Soroceanu L., Heike Y., Gillespie G.Y., Siegal G.P., Mao X., Bett A.J., Huckleet al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA. 95:1998;8795-8800.
70. Jeltsch M., Kaipainen A., Joukov V., Meng X., Lakso M., Rauvala H., Swartz M., Fukumura D., Jain R.K., Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 276:1997;1423-1425.
71. Detmar M., Brown L.F., Schon M.P., Elicker B.M., Velasco P., Richard L., Fukumura D., Monsky W., Claffey K.P., Jain R.K. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol. 111:1998;1-6.
72. Oh S.J., Jeltsch M.M., Birkenhager R., McCarthy J.E.G., Weich H.A., Christ B., Alitalo K., Wilting J. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol. 188:1997;96-109.
73. Witzenbichler B., Asahara T., Murohara T., Silver M., Spyridopoulos I., Magner M., Principe N., Kearney M., Hu J.-.S., Isner J.M. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol. 153:1998;381-394.
74. Cao Y., Linden P., Farnebo J., Cao R., Eriksson A., Kumar V., Qi J.-.H., Claesson-Welsh L., Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA. 95:1998;14389-14394. These results point to a dual role for VEGF-C both as an inducer of lymphanogenesis (see [70]) and angiogenesis.
75. Shalaby F., Ho J., Stanford W.L., Fischer K.D., Schuh A.C., Schwartz L., Bernstein A., Rossant J. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 89:1997;981-990.
76. Eichmann A., Corbel C., Nataf V., Vaigot P., Breant C., Le Douarin N.M. Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc Natl Acad Sci USA. 94:1997;5141-5146.
77. Sowter H.M., Corps A.N., Evans A.L., Clark D.E., Charnock-Jones D.S., Smith S.K. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest. 77:1997;607-614.
78. Salven P., Lymboussaki A., Heikkila P., Jaaskela-Saari H., Enholm B., Aase K., von Euler G., Eriksson U., Alitalo K., Joensuu H. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol. 153:1998;103-108.
79. Tsurusaki T., Kanda S., Sakai H., Kanetake H., Saito Y., Alitalo K., Koji T. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer. 80:1999;309-313.
80. Valtola R., Salven P., Heikkila P., Taipale J., Joensuu H., Rehn M., Pihlajaniemi T., Weich H., deWaal R., Alitalo K. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancers. Am J Pathol. 154:1999;1381-1390.
81. Takeshita S., Pu L.Q., Stein L.A., Sniderman A.D., Bunting S., Ferrara N., Isner J.M., Symes J.F. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation. 90:1994;228-234.
82. Asahara T., Bauters C., Pastore C., Kearney M., Rossow S., Bunting S., Ferrara N., Symes J.F., Isner J.M. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation. 91:1995;2793-2801.
83. Isner J.M., Pieczek A., Schainfeld R., Blair R., Haley L., Asahara T., Rosenfield K., Razvi S., Walsh K., Symes J.F. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 348:1996;370-374.
84. Baumgartner I., Pieczek A., Manor O., Blair R., Kearney M., Walsh K., Isner J.M. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 97:1998;1114-1123.
85. Davis S., Yancopoulos G.D. The angiopoietins: Yin Yang in angiogenesis. Curr Topics Microbiol Immunol. 237:1999;173-185.
86. Muller Y.A., Li B., Christinger H.W., Wells J.A., Cunningham B.C., de Vos A.M. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA. 94:1997;7192-7197.